hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo’ Khan takes Proactive's Stephen Gunnion through the company’s record-breaking financial performance in 2024, operational milestones and strategic outlook.
hVIVO reported a 12% rise in revenue to just under £63 million, with an EBITDA margin of 26%. Khan highlighted this as a record margin for the company. He noted that, even excluding a one-off facility fee, the margin remained strong at 23%. The company also ended the year with £44 million in cash.
Khan explained: “This is all been based on a record number of inoculations… we ran nine challenge trials and our largest field study to date.” He emphasised the company’s transformation, with a move to a purpose-built 50-bed human challenge facility in Canary Wharf, improvements in operational efficiency, and a major expansion of lab and outpatient capacity.
Looking ahead, hVIVO is targeting £73 million in revenue for 2025, of which £70 million is already contracted. The company is also launching new challenge models, including Omicron and hMPV, and pursuing its first phase 3 human trial.
Khan also discussed recent acquisitions—CRS in Germany and Cryostore in the UK—and confirmed continued dividend payments, with 0.2p per share set for June.
For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future updates.
#hVIVO #ClinicalTrials #HumanChallengeTrials #BiotechNews #EBITDA #RevenueGrowth #Biopharma #DrugDevelopment #CRSAcquisition #CryoStore #VaccineTrials #AntiviralResearch #LifeSciences #PharmaPipeline
